Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 18;26(18):5679.
doi: 10.3390/molecules26185679.

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Yongjie Chen  1 , Lijuan Bai  1 , Pu Zhang  1 , Hua Zhao  1 , Qianxiong Zhou  2
Affiliations
Review

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Yongjie Chen et al. Molecules. .

Abstract

Photoactivated chemotherapy (PACT) is a novel cancer treatment method that has drawn increasing attention due to its high selectivity and low side effects by spatio-temporal control of irradiation. Compared with photodynamic therapy (PDT), oxygen-independent PACT is more suitable for treating hypoxic tumors. By finely tuning ligand structures and coordination configurations, many Ru(II) complexes can undergo photoinduced ligand dissociation, and the resulting Ru(II) aqua species and/or free ligands may have anticancer activity, showing their potential as PACT agents. In this mini-review, we summarized the progress in Ru(II)-based PACT agents, as well as challenges that researchers in this field still face.

Keywords: Ru(II) complexes; photoactivated chemotherapy (PACT); photoinduced ligand dissociation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinically approved Pt (II) anticancer drugs.
Figure 2
Figure 2
Three ruthenium(III) complexes in clinical trials.
Figure 3
Figure 3
Jablonski diagram of Ru(II) complexes with photolabile ligands.
Figure 4
Figure 4
Ru(II) polypyridyl complexes with photolabile monodentate ligands.
Figure 5
Figure 5
Ru(II) polypyridyl complexes with photolabile bidentate ligands.
Figure 6
Figure 6
Photoactivatable Ru(II) polypyridyl complexes upon long-wavelength light irradiation.
Figure 7
Figure 7
Ru(II) complexes with dual PACT and PDT activity.
Figure 8
Figure 8
Ru(II) PACT agents with photolabile bioactive molecules.
Figure 9
Figure 9
Dual-activatable Ru(II) PACT agents.
Figure 10
Figure 10
Ru(II)-arene-complexes-based PACT agents.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Romero-Canelón I., Sadler P.J. Next-generation metal anticancer complexes: Multitargeting via redox modulation. Inorg. Chem. 2013;52:12276–12291. doi: 10.1021/ic400835n. - DOI - PubMed
    1. Mjos K.D., Orvig C. Metallodrugs in Medicinal Inorganic Chemistry. Chem. Rev. 2014;114:4540–4563. doi: 10.1021/cr400460s. - DOI - PubMed
    1. Das U., Kar B., Pete S., Paira P. Ru(II), Ir(III), Re(I) and Rh(III) based complexes as next generation anticancer metallopharmaceuticals. Dalton Trans. 2021;50:11259–11290. doi: 10.1039/D1DT01326B. - DOI - PubMed
    1. Ma D.L., He H.Z., Leung K.H., Chan D.S., Leung C.H. Bioactive luminescent transition-metal complexes for biomedical applications. Angew. Chem. Int. Ed. 2013;52:7666–7682. doi: 10.1002/anie.201208414. - DOI - PubMed
    1. Ohata J., Ball Z.T. Rhodium at the chemistry-biology interface. Dalton Trans. 2018;47:14855–14860. doi: 10.1039/C8DT03032D. - DOI - PubMed

MeSH terms

LinkOut - more resources